Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement

Myeloid/lymphoid neoplasms with eosinophilia are driven by aberrant tyrosine kinases in pluripotent cells and display variable phenotypes. FGFR-driven hematolymphoid neoplasms are targetable by TKI inhibitors such as ponatinib; studies of specific FGFR inhibitors are ongoing.

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood Adv
Egile Nagusiak: Carll, Timothy, Patel, Anand, Derman, Benjamin, Hyjek, Elizabeth, Lager, Angela, Wanjari, Pankhuri, Segal, Jeremy, Odenike, Olatoyosi, Fidai, Shiraz, Arber, Daniel
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2020
Gaiak:
Exceptional Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7556145/
https://ncbi.nlm.nih.gov/pubmed/33049052
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001282
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak